Erasca disclosed preliminary Phase 1 dose‑escalation data for its lead pan‑RAS molecular glue ERAS‑0015, reporting an unconfirmed objective response rate of 62 % in patients with second‑line or later KRAS‑G12X non‑small cell lung cancer and 40 % in second‑line KRAS‑G12X pancreatic cancer. The responses were observed across the pharmacologically active 16‑32 mg daily dose range, with partial responses noted even at the lowest 8 mg dose. The data are preliminary and unconfirmed, and the company cautions that future results may differ.
The data cut‑off dates were April 4 2026 for the U.S. AURORAS‑1 trial and February 27 2026 for the China‑based JYP0015M101 trial. Erasca began expansion and combination dose‑escalation cohorts in the first and second quarters of 2026, with readouts expected in the first half of 2027. The company notes that cross‑trial comparisons should be interpreted carefully, as the studies were conducted in different geographic regions and patient populations.
Safety data include a single Grade 3 pneumonitis event that progressed to Grade 5, the only fatal case reported to date. Erasca states that pneumonitis is a rare side effect of many cancer drugs and that no other Grade 4 or 5 events have occurred on ERAS‑0015. The company emphasizes that the safety profile remains generally well‑tolerated, with most adverse events being low‑grade.
Erasca’s CEO and chairman Jonathan E. Lim said, 'We are thrilled with the robust efficacy results demonstrated so far by our pan‑RAS inhibitor ERAS‑0015 in patients with lung and pancreatic cancer. The magnitude of clinical benefit seen during dose escalation is particularly striking and compares favorably with other pan‑RAS, pan‑KRAS, or KRAS‑mutant selective inhibitors. This efficacy is accompanied by generally well‑tolerated safety results, primarily characterized by manageable, low‑grade adverse events.' He added, 'Notably, preliminary data support ERAS‑0015 may be combined with standard‑of‑care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens. Together, we believe these findings support the best‑in‑class potential of ERAS‑0015, and we look forward to continued progress in our Phase 1 monotherapy dose expansion cohorts and combination dose escalation cohorts.' The company is positioning ERAS‑0015 against Revolution Medicines’ daraxonrasib, which holds FDA Breakthrough Therapy Designation for metastatic pancreatic cancer. A letter from Revolution Medicines alleging patent infringement and trade‑secret misuse adds a legal headwind to the clinical promise.
Investors have expressed concern about the safety signal and the legal dispute, tempering enthusiasm for the early efficacy data. Despite the promising clinical activity, the company’s cautious outlook and the single fatal pneumonitis case underscore the need for continued safety monitoring as the program advances.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.